Next-Generation alzheImer'S Therapeutics

NARecruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 19, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

February 28, 2027

Conditions
Alzheimer Disease
Interventions
OTHER

genetically encoded engineered proteins

using genetically encoded engineered proteins to obtain an inducible control of their activity in living human neurons promoting synaptic plasticity and/or preventing dendritic spines loss

Trial Locations (1)

00168

RECRUITING

Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER